---
schema_version: "secwatch.filing_event.v1"
accession: "0001650664-26-000027"
form_type: "8-K"
ticker: "EDIT"
cik: "0001650664"
company_name: "Editas Medicine, Inc."
filed_at: "2026-03-27T23:59:59+00:00"
generated_at: "2026-05-15T08:39:02.862732+00:00"
event_type: "regulatory"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# USPTO reaffirms Broad Institute's CRISPR/Cas9 patent priority; Editas' licensed patents upheld

## Summary
- PTAB issued third favorable decision for Broad over CVC on CRISPR/Cas9 editing in eukaryotic cells.
- CVC retains the right to appeal to the U.S. Court of Appeals for the Federal Circuit.
- Editas' exclusive license to the CRISPR/Cas9 patents at issue remains intact; other in-licensed patents not impacted.
- CEO Gilmore O'Neill cites confidence in IP, highlighting EDIT-401 with >90% mean LDL reduction in NHPs.

## SEC filing metadata
- accession: 0001650664-26-000027
- form_type: 8-K
- ticker: EDIT
- cik: 0001650664
- company_name: Editas Medicine, Inc.
- filed_at: 2026-03-27T23:59:59+00:00
- event_type: regulatory
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1650664/000165066426000027/0001650664-26-000027-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1650664/000165066426000027/edit-20260326.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001650664-26-000027
- JSON: https://secwatch.observer/filing/0001650664-26-000027.json
- Plain text: https://secwatch.observer/filing/0001650664-26-000027.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.